ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $8.18M rose 1.3% year over year, behind the +12.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 11 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +15.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.18M-5.9% QoQ
- Last fiscal yearDec 2025
- $33.19M+15.1% YoY
- LTMMar 2026
- $33.29M+12.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.3% | -100.0% | -101.3 pp |
| 1 year | +15.1% | -100.0% | -115.1 pp |
| 3-year CAGR | +9.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 33.19M USD
- Year-over-year change
- +15.1%
- 4-year CAGR
- +10.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.19M | +15.1% |
| FY2024 | 2024-12-31 | 28.82M | +12.6% |
| FY2023 | 2023-12-31 | 25.61M | +2.1% |
| FY2022 | 2022-12-31 | 25.09M | +14.0% |
| FY2021 | 2021-12-31 | 22.01M | — |
Selling, General & Admin vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 selling, general & admin of $33.29M is the 7th highest of the 11 companies compared; the peer median is $37.28M.
- Its year-over-year change of +12.6% is the 9th highest of 11, against a peer median of +29.7%.
- Over three fiscal years its annual growth of +9.8% compares with a peer median of +35.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $176.24M | +26.9% | +75.5% | 81.2% | |
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Mar 2026 | $88.42M | +83.1% | +48.1% | 178.3% | |
| LTM Mar 2026 | $42.56M | -1.1% | +23.3% | 196.9% | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Sep 2026 | $36.41M | +35.2% | +63.3% | — | |
| LTM Mar 2026 | $33.29M | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $31.48M | +21.6% | +23.3% | — | |
| LTM Mar 2026 | $27.19M | +59.1% | +55.2% | — | |
| LTM Mar 2026 | $10.49M | +24.0% | +4.5% | — | |
| LTM Mar 2026 | $9.69M | +36.8% | +16.2% | — | |
| Peer median (excluding ORIC) | $37.28M | +29.7% | +35.7% | 93.3% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.